Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Aug;69(4):288–304. doi: 10.1016/j.curtheres.2008.08.001

Gabexate mesylate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis update

Ming-Hua Zheng 1,†, Jian-Ling Bai 2, Mao-Bin Meng 3, Yong-Ping Chen 1,‡
PMCID: PMC3969935  PMID: 24692807

Abstract

Background: Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP), and the benefit of pharmacologic treatment of the condition is unclear. Although prophylactic use of gabexate mesylate (GM) for the reduction of pancreatic injury after ERCP has been evaluated, uncertainty remains regarding the effectiveness of GM treatment in post-ERCP pancreatitis (PEP).

Objective: The aim of this study was to determine through systematic review and meta-analysis the effectiveness and tolerability of GM in the prophylaxis of PEP.

Methods: MEDLINE (January 1966–July 2007), EMBASE (January 1966– July 2007), the Cochrane Controlled Trials Register on The Cochrane Library (Issue 2, 2007), and the China Biological Medicine Database (January 1978–July 2007) were searched. We used the method recommended by The Cochrane Collaboration to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) of GM in the prevention of PEP.

Results: Of the 38 studies identified, 31 were excluded for the following reasons: they were reviews or editorials (9 articles); were meta-analyses (4); had differences in cointerventions (4); were nonrandomized controlled trials or had incorrect randomization (4); were repeat publications (2); lacked a placebo group (1); or other (7). Seven RCTs, totaling 2883 patients, conducted in a variety of languages were included in the meta-analysis. When the RCTs were analyzed, odds ratios for GM were 0.65 (95% CI, 0.36–1.18; P 0.16) for PER 1.90 (95% CI, 0.54–6.65; P 0.32) for severe PEP, 0.55 (95% CI, 0.17–1.77; P 0.32) for the case-fatality ratio of PEP, 0.88 (95% CI, 0.74–1.05; P 0.16) for post-ERCP hyperamylasemia, and 0.78 (95% CI, 0.49 1.25; P 0.30) for post-ERCP abdominal pain. No evidence of publication bias was found.

Conclusions: No beneficial effects of GM on acute pancreatitis, the PEP mortality rate, or post-ERCP abdominal pain or hyperamylasemia were found; therefore, GM cannot be recommended for the prophylaxis of PEP.

Key Words: gabexate mesylate, post-endoscopic retrograde cholangiopancreatography pancreatitis, prevention, randomized controlled trial, meta-analysis

Full Text

The Full Text of this article is available as a PDF (814.9 KB).

Contributor Information

Mao-Bin Meng, Email: blueman1320@163.com.

Yong-Ping Chen, Email: ypchen77@hotmail.com.

References

  • 1.Zheng M, Chen Y, Yang X. Gabexate in the prophylaxis of post-ERCP pancreatitis: A meta-analysis of randomized controlled trials. BNC Gastroenterol. 2007;7:6. doi: 10.1186/1471-230X-7-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Andriulli A, Leandro G, Federici T. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: An updated meta-analysis. Gastrointest Endosc. 2007;65:624–632. doi: 10.1016/j.gie.2006.10.030. [DOI] [PubMed] [Google Scholar]
  • 3.Andriulli A, Leandro G, Niro G. Pharmacologic treatment can prevent pancreatic injury after ERCP: A meta-analysis. Gastrointest Endosc. 2000;51:1–7. doi: 10.1016/s0016-5107(00)70377-4. [DOI] [PubMed] [Google Scholar]
  • 4.Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: A comprehensive review. Gastrointest Endosc. 2004;59:845–864. doi: 10.1016/s0016-5107(04)00353-0. [DOI] [PubMed] [Google Scholar]
  • 5.Sherman S, Lehman GA. ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas. 1991;6:350–367. doi: 10.1097/00006676-199105000-00013. [published correction appears in Pancreas, 1992;7:402] [DOI] [PubMed] [Google Scholar]
  • 6.Cotton PB, Lehman G, Vennes J. Endoscopic sphincterotomy complications and their management: An attempt at consensus. Gastrointest Endosc. 1991;37:383–393. doi: 10.1016/s0016-5107(91)70740-2. [DOI] [PubMed] [Google Scholar]
  • 7.Benini L, Angelini G, Lavarini E. Effect of a new enzyme inhibitor (gabexate mesilate- FOY) on hyperenzymemia induced by ERCP: A double blind study. Digestion. 1985;32:165. Abstract. [Google Scholar]
  • 8.Cavallini G, Tittobello A, Frulloni L. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy—Italian Group. N Engl J Med. 1996;335:919–923. doi: 10.1056/NEJM199609263351302. [DOI] [PubMed] [Google Scholar]
  • 9.Andriulli A, Clemente R, Solmi L. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 2002;56:488–495. doi: 10.1067/mge.2002.128130. [DOI] [PubMed] [Google Scholar]
  • 10.Andriulli A, Solmi L, Loperfido S. Prophylaxis of ERCP-related pancreatitis: A randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol. 2004;2:713–718. doi: 10.1016/s1542-3565(04)00295-2. [DOI] [PubMed] [Google Scholar]
  • 11.Xiong GS, Wu SM, Zhang XW, Ge ZZ. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res. 2006;39:85–90. doi: 10.1590/s0100-879x2006000100010. [DOI] [PubMed] [Google Scholar]
  • 12.Benvenuti S, Zancanella L, Piazzi L. Prevention of post-ERCP pancreatitis with somato-statin versus gabexate mesilate: A randomized placebo-controlled multicenter study. Dig Liv Dis. 2006;38:S15. Abstract. [Google Scholar]
  • 13.Manes G, Ardizzone S, Lombardi G. Efficacy ofpostprocedure administration ofgabexate mesylate in the prevention of post-ERCP pancreatitis: A randomized, controlled, multicenter study. Gastrointest Endosc. 2007;65:982–987. doi: 10.1016/j.gie.2007.02.055. [DOI] [PubMed] [Google Scholar]
  • 14.Jadad AR, Moore RA, Carroll D. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4. [DOI] [PubMed] [Google Scholar]
  • 15.Altman DG, Schulz KE. Statistics notes: Concealing treatment allocation in randomised trials. BMJ. 2001;323:446–447. doi: 10.1136/bmj.323.7310.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Moher D, Pham B, Jones A. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609–613. doi: 10.1016/S0140-6736(98)01085-X. [DOI] [PubMed] [Google Scholar]
  • 17.Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] 2008. www.cochranehandbook.org The Cochrane Collaboration. Accessed March 18, 2008. [Google Scholar]
  • 18.Moher D, Cook DJ, Eastwood S. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896–1900. doi: 10.1016/s0140-6736(99)04149-5. [DOI] [PubMed] [Google Scholar]
  • 19.Shimizu Y, Takahashi H, Deura M. Prophylactic effects of preoperative administration of gabexate mesilate (FOY) on post-ERCP pancreatitis. Gendai Iryo. 1979;11:540–544. [Google Scholar]
  • 20.Kuno N, Kasugai T, Oguri T, Matsuura A. Study on prevention of complication associated with endoscopic retrograde cholangiopancreatography (ERCP): A controlled trial of a new protease inhibitor, FOY, in hyperamylasemia following endoscopic retrograde cholangiopancreatography. Gendai Iryo. 1978;10:571–575. [Google Scholar]
  • 21.Hajiro K, Tsujimura D, Inoue R. Effect of FOY on hyperamylasemia after endoscopic retrograde cholangiopancreatography. Gendai Iryo. 1978;10:1375–1379. [Google Scholar]
  • 22.Masci E, Cavallini G, Mariani A, Gabexte in Digestive Endoscopy-Italian Group II Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol. 2003;98:2182–2186. doi: 10.1111/j.1572-0241.2003.07698.x. [DOI] [PubMed] [Google Scholar]
  • 23.Wang J, Cai ZF, Jiao CW. Prevention of post-ERCP pancreatitis. J Hepatopancreatobiliary Surg. 2006;18:34–35. [Google Scholar]
  • 24.Xiong GS, Zhang XW, Wu SM. Prophylactic effect of gabexate on post-ERCP pancreatitis: A clinical observation. Chinese J Pancreatol. 2005;5:200–202. [Google Scholar]
  • 25.Cao XP, Tu ZX. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial. Chinese J Pancreatol. 2003;3:219. doi: 10.1067/mge.2002.128130. [DOI] [PubMed] [Google Scholar]
  • 26.Andriulli A, Caruso N, Quitadamo M. Antisecretory vs antiproteasic drugs in the prevention of post-ERCP pancreatitis: The evidence-based medicine derived from a meta-analysis study. JOE. 2003;4:41–48. [PubMed] [Google Scholar]
  • 27.Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BNJ. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101. [PubMed] [Google Scholar]
  • 29.Prat F, Amaris J, Ducot B. Nifedipine for prevention of post-ERCP pancreatitis: A prospective, double-blind randomized study. Gastrointest Endosc. 2002;56:202–208. doi: 10.1016/s0016-5107(02)70178-8. [DOI] [PubMed] [Google Scholar]
  • 30.Odes HS, Novis BN, Barbezat GO, Bank S. Effect of calcitonin on the serum amylase levels after endoscopic retrograde cholangiopancreatography. Digestion. 1977;16:180–184. doi: 10.1159/000198070. [DOI] [PubMed] [Google Scholar]
  • 31.Brust R, Thomson AB, Wensel RH. Pancreatic injury following ERCP. Failure of prophylactic benefit of Trasylol. Gastrointest Endosc. 1977;24:77–79. doi: 10.1016/s0016-5107(77)73457-1. [DOI] [PubMed] [Google Scholar]
  • 32.Silvis SE, Vennes JA. The role ofglucagon in endoscopic cholangiopancreatography. Gastrointest Endosc. 1975;21:162–163. doi: 10.1016/s0016-5107(75)73837-3. [DOI] [PubMed] [Google Scholar]
  • 33.Arcidiacono R, Gambitta P, Rossi A. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy. 1994;26:715–718. doi: 10.1055/s-2007-1009081. [DOI] [PubMed] [Google Scholar]
  • 34.Sternlieb JM, Aronchick CA, Retig JN. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol. 1992;87:1561–1566. [PubMed] [Google Scholar]
  • 35.Binmoeller KF, Harris AG, Dumas R. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut. 1992;33:1129–1133. doi: 10.1136/gut.33.8.1129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Tulassay Z, Papp J. The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography. Gastrointest Endosc. 1991;37:48–50. doi: 10.1016/s0016-5107(91)70620-2. [DOI] [PubMed] [Google Scholar]
  • 37.Zheng M, Chen Y, Jian L, et al, Meta-analysis of prophylactic allopurinol use in post-ERCP pancreatitis. Pancreas. In press. [DOI] [PubMed]
  • 38.Zheng M, Bai J, Yuan B. Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol. 2008;8:6. doi: 10.1186/1471-230X-8-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Murray B, Carter R, Imrie C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003;124:1786–1791. doi: 10.1016/s0016-5085(03)00384-6. [DOI] [PubMed] [Google Scholar]
  • 40.Saluja AK, Steer ML. Pathophysiology of pancreatitis. Role of cytokines and other mediators of inflammation. Digestion. 1999;60(Suppl 1):27–33. doi: 10.1159/000051450. [DOI] [PubMed] [Google Scholar]
  • 41.Ohshio G, Saluja AK, Leli U. Esterase inhibitors prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis. Gastroenterology. 1989;96:853–859. [PubMed] [Google Scholar]
  • 42.Borzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med. 1995;123:873–877. doi: 10.7326/0003-4819-123-11-199512010-00010. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES